Mesoblast (MESO) Receivables (2015 - 2025)
Mesoblast (MESO) posted Receivables of $43.3 million for Q4 2025, up 191.27% sequentially from $14.9 million in Q2 2025, and up 106.66% YoY from $21.0 million in Q4 2024.
Mesoblast (MESO) Receivables (2015 - 2025) Analysis & Trends
Mesoblast has reported Receivables for 11 years, with the latest figure at $43.3 million in Q4 2025.
- Quarterly Receivables rose 106.66% year-over-year to $43.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $43.3 million (up 106.66% YoY) and the FY2025 annual result came in at $14.9 million, down 29.05% from the prior year.
- Receivables climbed to $43.3 million in Q4 2025 per MESO's latest filing, from $14.9 million in the prior quarter.
- Over five years, Receivables peaked at $43.3 million in Q4 2025 and troughed at $2.9 million in Q1 2021.
- A 5-year average of $10.4 million and a median of $5.6 million in 2022 frame the typical range for Receivables.
- The sharpest annual moves came in 2021 and 2022: Receivables surged 207.62% in 2021, then slumped 31.35% in 2022.
- Over 5 years, Receivables stood at $6.0 million in 2021, then declined by 27.2% to $4.4 million in 2022, then soared by 58.94% to $7.0 million in 2023, then surged by 199.4% to $21.0 million in 2024, then jumped by 106.66% to $43.3 million in 2025.
- According to Business Quant data, Receivables over the past three periods registered $43.3 million, $14.9 million, and $21.0 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Mesoblast | 2.01 Bn | 1.87 Bn | - | 43.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 43.30 Mn |
| Jun 30, 2025 | 14.87 Mn |
| Dec 31, 2024 | 20.95 Mn |
| Jun 30, 2024 | 20.95 Mn |
| Dec 31, 2023 | 7.00 Mn |
| Jun 30, 2023 | 7.00 Mn |
| Mar 31, 2023 | 4.40 Mn |
| Dec 31, 2022 | 4.40 Mn |
| Sep 30, 2022 | 3.86 Mn |
| Jun 30, 2022 | 4.40 Mn |
| Mar 31, 2022 | 5.63 Mn |
| Dec 31, 2021 | 6.05 Mn |
| Sep 30, 2021 | 5.63 Mn |
| Jun 30, 2021 | 4.84 Mn |
| Mar 31, 2021 | 2.95 Mn |
| Dec 31, 2020 | 3.34 Mn |
| Sep 30, 2020 | 2.45 Mn |
| Jun 30, 2020 | 1.57 Mn |
| Mar 31, 2020 | 3.00 Mn |
| Dec 31, 2019 | 3.09 Mn |